Last $189,300 COP
Change Today 0.00 / 0.00%
Volume 0.0
As of 4:01 PM 08/1/14 All times are local (Market data is delayed by at least 15 minutes).

johnson & johnson (JNJ) Snapshot

Open
--
Previous Close
$189,300
Day High
--
Day Low
--
52 Week High
08/1/14 - $134,218
52 Week Low
08/1/14 - $134,218
Market Cap
--
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
2.8B
EX-Date
02/20/15
P/E TM
--
Dividend
$2.78
Dividend Yield
2.92%
Current Stock Chart for JOHNSON & JOHNSON (JNJ)

johnson & johnson (JNJ) Details

Johnson & Johnson, together with its subsidiaries, is engaged in the research and development, manufacture, and sale of various products in the health care field worldwide. The company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. The Consumer segment offers a range of products used in the baby care, skin care, oral care, wound care, and women’s health fields, as well as nutritionals, over-the-counter pharmaceutical products, and wellness and prevention platforms under the JOHNSON’S, AVEENO, CLEAN & CLEAR, DABAO, JOHNSON’S Adult, LUBRIDERM, NEUTROGENA, RoC, VENDÔME, LISTERINE, BAND-AID, NEOSPORIN, STAYFREE, CAREFREE, o.b. tampon, SPLENDA, TYLENOL, SUDAFED, ZYRTEC, MOTRIN IB, and PEPCID brand names. This segment markets its products to the general public, as well as to retail outlets and distributors. The Pharmaceutical segment provides various products in the areas of anti-infective, antipsychotic, cardiovascular, contraceptive, gastrointestinal, hematology, immunology, infectious diseases, metabolic, neurology, oncology, pain management, thrombosis, and vaccines. This segment distributes its products directly to retailers, wholesalers, and health care professionals for prescription use. The Medical Devices and Diagnostics segment offers various products to treat cardiovascular disease; orthopaedic and neurological products; general surgery, biosurgical, and energy products; professional diagnostic products; infection prevention products; and disposable contact lenses. This segment distributes its products to wholesalers, hospitals, and retailers, used principally in the professional fields by physicians, nurses, hospitals, and clinics. Johnson & Johnson was founded in 1885 and is based in New Brunswick, New Jersey.

126,500 Employees
Last Reported Date: 01/20/15
Founded in 1885

johnson & johnson (JNJ) Top Compensated Officers

Chairman, Chief Executive Officer, Chairman o...
Total Annual Compensation: $1.5M
Chief Financial Officer, Vice President of Fi...
Total Annual Compensation: $842.3K
Group Worldwide Chairman and Member of Execut...
Total Annual Compensation: $2.7M
Worldwide Chairman of Pharmaceuticals, Chief ...
Total Annual Compensation: $952.9K
Vice President, General Counsel and Member of...
Total Annual Compensation: $542.3K
Compensation as of Fiscal Year 2013.

johnson & johnson (JNJ) Key Developments

Johnson & Johnson Provides Earnings Guidance for the Full Year 2015

Johnson & Johnson provided earnings guidance for the full year 2015. The company forecast full-year 2015 earnings ranging from $6.12 to $6.27 per share - well above the $5.52 in adjusted earnings per share it generated for all of 2014.

Johnson & Johnson Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 28, 2014

Johnson & Johnson reported unaudited consolidated earnings results for the fourth quarter and full year ended December 28, 2014. For the quarter, sales to customers were $18,254 million against $18,355 million a year ago. Earnings before provision for taxes on income were $2,703 million against $2,750 million a year ago. Net earnings were $2,521 million against $3,519 million a year ago. Diluted net earnings per share were $0.89 against $1.23 a year ago. Adjusted earnings before provision for taxes and net earnings before provision for taxes on income was $3,925 million against $3,909 million a year ago. Diluted net earnings per share were $1.27 against $1.24 a year ago. For the full year, sales to customers were $74,331 million against $71,312 million a year ago. Earnings before provision for taxes on income were $20,563 million against $15,471 million a year ago. Net earnings were $16,323 million against $13,831 million a year ago. Diluted net earnings per share were $5.70 million against $4.81 million a year ago. Adjusted earnings before provision for taxes and net earnings before provision for taxes on income was $21,195 million against $19,169 million a year ago. Net earnings were $17,105 million against $15,876 million a year ago. Diluted net earnings per share were $5.97 against $5.52 million a year ago.

Depomed Inc. to Buy Pain Drug from Johnson and Johnson for $1.05 Billion

Depomed Inc. will buy a pain drug from Johnson and Johnson for $1.05 billion, adding a product to its pain and neurology portfolio. Depomed will take the rights to tapentadol hydrochloride (Nucynta), an opioid pain pill that sold $166 million in the 1-year period that ended in September. Depomed said it plans to reintroduce the drug and promote it for both chronic pain and nerve damage caused by diabetes. The medicine has patent protection until 2022.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
JNJ:CB $189,300.00 COP 0.00

JNJ Competitors

Market data is delayed at least 15 minutes.

Company Last Change
General Electric Co $23.84 USD 0.00
Intel Corp $33.78 USD 0.00
International Business Machines Corp $151.55 USD 0.00
Merck & Co Inc $61.45 USD 0.00
Roche Holding AG SFr.251.10 CHF -0.60
View Industry Companies
 

Industry Analysis

JNJ

Industry Average

Valuation JNJ Industry Range
Price/Earnings 17.9x
Price/Sales 3.9x
Price/Book 3.7x
Price/Cash Flow 17.5x
TEV/Sales 3.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact JOHNSON & JOHNSON, please visit www.jnj.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.